Acumen Pharmaceuticals Inc. (ABOS)
ABOS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ABOS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001576885 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern." | 10-Q 2026-10-26 |
| Cash and burn | $53.1M cash; operating cash flow -$22.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 72,327,320 (2026-10-21); 60,573,425 a year earlier; 57,910,461 three years earlier. | Cover page 2026-10-21 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $592K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$25.4M | -$26.7M | $53.1M | $26.3M | Needs four quarters | 10-Q 2026-10-26 |
| Q2 2026 2026-06-30 | Not filed | -$32.7M | -$18.1M | $59.4M | $31.6M | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$20.7M | -$24.1M | $51.8M | $31.0M | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | Not filed | -$25.1M | -$19.1M | $54.0M | $31.2M | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$26.5M | -$30.5M | $46.8M | $30.7M | Needs four quarters | 10-Q 2026-10-26 |
| Q2 2025 2025-06-30 | Not filed | -$41.0M | -$31.8M | $36.8M | $29.9M | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$28.8M | -$34.1M | $30.2M | $29.5M | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | Not filed | -$37.2M | -$27.2M | $35.6M | $29.4M | Needs four quarters | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-10-26 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-10-26 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 365 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.5% |
| 1 month | -88.2% |
| 3 months | -91.6% |
| Year to date | -89.9% |
| 1 year | -88.2% |
| From 52-week high | -93.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PLUR | Pluri Inc. | $1.04 | -0.95% | $15.0M |
| ESLA | Estrella Immunopharma Inc. | $0.3800 | -26.07% | $16.5M |
| ATYR | aTyr Pharma Inc. | $5.24 | -14.17% | $13.4M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
| BSEM | BioStem Technologies Inc. | $0.9601 | -8.56% | $18.4M |
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier